Beigene, Ltd. (NASDAQ:ONC) CEO Sells $14,596,526.70 in Stock

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 58,590 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $249.13, for a total transaction of $14,596,526.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

John Oyler also recently made the following trade(s):

• On Monday, March 3rd, John Oyler sold 101,000 shares of Beigene stock. The stock was sold at an average price of $244.30, for a total transaction of $24,674,300.00.

Beigene Stock Performance

NASDAQ ONC opened at $247.07 on Friday. The firm has a market cap of $24.18 billion, a P/E ratio of -29.98, a price-to-earnings-growth ratio of 7.73 and a beta of 0.65. Beigene, Ltd. has a 1 year low of $126.97 and a 1 year high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.

Beigene (NASDAQ:ONC) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. As a group, analysts predict that Beigene, Ltd. will post -5.82 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ONC shares. Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and raised their price target for the stock from $207.00 to $320.00 in a report on Monday, March 3rd. Macquarie boosted their target price on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a research report on Friday, February 28th.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.